Author: Chen, Dong; Yang, Bo; Zhang, Yan; Chen, Liang; Wei, Lai; Zhang, Weijie; Wang, Xinqiang; Tong, Xiaolin; Chen, Zhishui
Title: Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report Cord-id: mzf9fiy5 Document date: 2020_6_12
ID: mzf9fiy5
Snippet: RATIONALE: Coronavirus disease 2019 (COVID-19) is a novel infectious disease and became a global issue. Treatment of COVID-19 especially in solid organ transplant recipients is empirical and controversial, especially the adjustment of the immunosuppressants. PATIENT CONCERNS: A 29-year-old kidney transplant recipient with the symptoms of COVID-19 pneumonia. DIAGNOSES: COVID-19 pneumonia after kidney transplantation. INTERVENTIONS: He was treated with modified immunosuppressants (unchanged dose o
Document: RATIONALE: Coronavirus disease 2019 (COVID-19) is a novel infectious disease and became a global issue. Treatment of COVID-19 especially in solid organ transplant recipients is empirical and controversial, especially the adjustment of the immunosuppressants. PATIENT CONCERNS: A 29-year-old kidney transplant recipient with the symptoms of COVID-19 pneumonia. DIAGNOSES: COVID-19 pneumonia after kidney transplantation. INTERVENTIONS: He was treated with modified immunosuppressants (unchanged dose of tacrolimus and oral corticosteroids while discontinuing mycophenolate mofetil (MMF)), antibiotics, interferon α-2b inhalation and traditional Chinese medicine. OUTCOMES: He recovered from COVID-19 pneumonia after 29 days of hospitalization. And the renal function (measured as blood urea nitrogen, serum creatinine, and urine protein) returned to normal. LESSONS: In certain group of COVID-19 (e.g., mild to moderate cases, young patients without comorbidities), a reduction instead of an overall withdrawal of immunosuppressant in kidney transplant recipients is feasible.
Search related documents:
Co phrase search for related documents- activation proliferation and lymphocyte activation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and local community: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long term short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low remain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and lung infiltrate: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome and lung infiltrate absorption: 1, 2
- acute respiratory syndrome and lymphocyte activation: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lymphocyte leukocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- acute respiratory syndrome and lymphocyte leukocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and lymphocyte therapy: 1, 2, 3
- local community and long term short term: 1, 2, 3
- local community and lymphocyte count: 1
- long term short term and low remain: 1
- long term short term and lymphocyte count: 1, 2, 3
- long term short term and lymphocyte therapy: 1
- lung infiltrate and lymphocyte therapy: 1
Co phrase search for related documents, hyperlinks ordered by date